D. Theegarten

Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event

Introduction Pulmonary embolism (PE) at initial diagnosis and during first-line systemic treatment is clinically relevant in patients with lung cancer. However, real-world incidence of subclinical PE is not well established. Methods Retrospective single-center analysis of patients at least 18 years old with non-small-c...